Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Comparative Effectiveness Research On Track To Be Resolved In Conference

This article was originally published in The Pink Sheet Daily

Executive Summary

Independent versus government-based CER group is one of issues likely to be left to House/Senate negotiators.
Advertisement

Related Content

CER And Personalized Medicine Are "Synergistic" - FDA's Woodcock
CER And Personalized Medicine Are "Synergistic" - FDA's Woodcock
Merged House Health Bill Seeks More Part D Drug Savings, Sets Broad Medicaid Expansion
Merged House Health Bill Seeks More Part D Drug Savings, Sets Broad Medicaid Expansion
Comparative Effectiveness In Coverage Decisions: Restrictions Added To House Health Reform Bill

Topics

Advertisement
UsernamePublicRestriction

Register

PS068676

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel